Overview

A4250, an IBAT Inhibitor in Pediatric Cholestasis

Status:
Completed

Trial end date:
2017-03-17

Target enrollment:

Participant gender:

Summary

This study will evaluate A4250 (IBATinhibitor) as a treatment option in pediatric patients with chronic cholestasis with main emphasis on safety evaluation and on effects on pruritus

Phase:

Phase 2

Details

Lead Sponsor:

Albireo